vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and STRATASYS LTD. (SSYS). Click either name above to swap in a different company.
STRATASYS LTD. is the larger business by last-quarter revenue ($137.0M vs $83.5M, roughly 1.6× BillionToOne, Inc.). BillionToOne, Inc. runs the higher net margin — 6.8% vs -40.6%, a 47.5% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs -2.2%). BillionToOne, Inc. produced more free cash flow last quarter ($6.5M vs $2.5M).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Stratasys, Ltd. is an American-Israeli manufacturer of 3D printers, software, and materials for polymer additive manufacturing as well as 3D-printed parts on-demand. The company is incorporated in Israel. Engineers use Stratasys systems to model complex geometries in a wide range of polymer materials, including: ABS, polyphenylsulfone (PPSF), polycarbonate (PC), polyetherimide and Nylon 12.
BLLN vs SSYS — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $137.0M |
| Net Profit | $5.7M | $-55.6M |
| Gross Margin | 69.9% | 41.0% |
| Operating Margin | 11.5% | -16.6% |
| Net Margin | 6.8% | -40.6% |
| Revenue YoY | 117.4% | -2.2% |
| Net Profit YoY | 138.3% | -109.0% |
| EPS (diluted) | $0.10 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $83.5M | $137.0M | ||
| Q2 25 | — | $138.1M | ||
| Q1 25 | — | $136.0M | ||
| Q3 24 | $38.4M | $140.0M | ||
| Q2 24 | — | $138.0M | ||
| Q1 24 | — | $144.1M | ||
| Q3 23 | — | $162.1M | ||
| Q2 23 | — | $159.8M |
| Q3 25 | $5.7M | $-55.6M | ||
| Q2 25 | — | $-16.7M | ||
| Q1 25 | — | $-13.1M | ||
| Q3 24 | $-14.9M | $-26.6M | ||
| Q2 24 | — | $-25.7M | ||
| Q1 24 | — | $-26.0M | ||
| Q3 23 | — | $-47.3M | ||
| Q2 23 | — | $-38.6M |
| Q3 25 | 69.9% | 41.0% | ||
| Q2 25 | — | 43.1% | ||
| Q1 25 | — | 44.3% | ||
| Q3 24 | 52.6% | 44.8% | ||
| Q2 24 | — | 43.8% | ||
| Q1 24 | — | 44.4% | ||
| Q3 23 | — | 40.5% | ||
| Q2 23 | — | 41.5% |
| Q3 25 | 11.5% | -16.6% | ||
| Q2 25 | — | -12.0% | ||
| Q1 25 | — | -9.1% | ||
| Q3 24 | -32.9% | -18.2% | ||
| Q2 24 | — | -18.9% | ||
| Q1 24 | — | -17.0% | ||
| Q3 23 | — | -26.4% | ||
| Q2 23 | — | -21.1% |
| Q3 25 | 6.8% | -40.6% | ||
| Q2 25 | — | -12.1% | ||
| Q1 25 | — | -9.6% | ||
| Q3 24 | -38.8% | -19.0% | ||
| Q2 24 | — | -18.6% | ||
| Q1 24 | — | -18.0% | ||
| Q3 23 | — | -29.2% | ||
| Q2 23 | — | -24.2% |
| Q3 25 | $0.10 | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | $-1.47 | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | $-0.68 | ||
| Q2 23 | — | $-0.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $71.5M |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $-239.5M | $852.5M |
| Total Assets | $327.5M | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $195.2M | $71.5M | ||
| Q2 25 | — | $71.1M | ||
| Q1 25 | — | $70.1M | ||
| Q3 24 | — | $64.0M | ||
| Q2 24 | — | $70.9M | ||
| Q1 24 | — | $91.1M | ||
| Q3 23 | — | $104.6M | ||
| Q2 23 | — | $144.4M |
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q3 25 | $-239.5M | $852.5M | ||
| Q2 25 | — | $902.4M | ||
| Q1 25 | — | $784.8M | ||
| Q3 24 | $-242.9M | $831.8M | ||
| Q2 24 | — | $850.5M | ||
| Q1 24 | — | $866.1M | ||
| Q3 23 | — | $883.1M | ||
| Q2 23 | — | $923.2M |
| Q3 25 | $327.5M | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.0B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B | ||
| Q3 23 | — | $1.2B | ||
| Q2 23 | — | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $6.9M |
| Free Cash FlowOCF − Capex | $6.5M | $2.5M |
| FCF MarginFCF / Revenue | 7.7% | 1.8% |
| Capex IntensityCapex / Revenue | 8.8% | 3.2% |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-11.5M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $13.8M | $6.9M | ||
| Q2 25 | — | $-1.1M | ||
| Q1 25 | — | $4.5M | ||
| Q3 24 | — | $-4.5M | ||
| Q2 24 | — | $-2.4M | ||
| Q1 24 | — | $7.3M | ||
| Q3 23 | — | $-12.7M | ||
| Q2 23 | — | $-23.2M |
| Q3 25 | $6.5M | $2.5M | ||
| Q2 25 | — | $-8.4M | ||
| Q1 25 | — | $789.0K | ||
| Q3 24 | — | $-6.3M | ||
| Q2 24 | — | $-4.9M | ||
| Q1 24 | — | $5.0M | ||
| Q3 23 | — | $-15.0M | ||
| Q2 23 | — | $-26.1M |
| Q3 25 | 7.7% | 1.8% | ||
| Q2 25 | — | -6.1% | ||
| Q1 25 | — | 0.6% | ||
| Q3 24 | — | -4.5% | ||
| Q2 24 | — | -3.6% | ||
| Q1 24 | — | 3.5% | ||
| Q3 23 | — | -9.3% | ||
| Q2 23 | — | -16.3% |
| Q3 25 | 8.8% | 3.2% | ||
| Q2 25 | — | 5.3% | ||
| Q1 25 | — | 2.8% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 1.8% | ||
| Q1 24 | — | 1.6% | ||
| Q3 23 | — | 1.4% | ||
| Q2 23 | — | 1.8% |
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
SSYS
Segment breakdown not available.
